Does COPD have a clinically relevant impact on hearing loss? A retrospective matched cohort study with selection of patients diagnosed with COPD

Gustav Kamenski,1 Jana Bendova,2 Waltraud Fink,3 Andreas Sön nichsen,4 Andreas Spiegel,5 Sonja Zehetmayer6

ABSTRACT

Objective: Chronic obstructive pulmonary disease (COPD) as a multisystemic disease has a measurable and biologically explainable impact on the auditory function detectable in the laboratory. This study tries to clarify if COPD is also a significant and clinically relevant risk factor for hearing impairment detectable in the general practice setting.

Design: Retrospective matched cohort study with selection of patients diagnosed with COPD.

Setting: 12 general practices in Lower Austria.

Participants: Consecutive patients >35 years with a diagnosis of COPD. Those who agreed were individually 1:1 matched with controls according to age, sex, hypertension, diabetes, coronary heart disease and chronic heart failure.

Main outcome measures:Sensorineural hearing impairment as assessed by pure tone audiometry, answers of three questions concerning a self-perceived hearing problem, application of the whispered voice test and the score of the Hearing Inventory for the Elderly, Screening Version (HHIE-S).

Results: 194 patients (97 pairs of 194 cases and controls) with a mean age of 65.5 (SD 10.2) were tested. Univariate conditional logistic regression resulted in significant differences in the mean bone conduction hearing loss and in the total score of HHIE-S, in the multiple conditional regression model, only smoking (p<0.0001) remained significant.

Conclusions: The results of this study do not support the hypothesis that there is an association between COPD and hearing impairment which, if found, would have allowed better management of patients with COPD.

INTRODUCTION

There is increasing evidence that chronic obstructive pulmonary disease (COPD) as a multisystemic disease has a significant number of comorbidities.1,3 COPD can also directly affect some organ systems including the central nervous system. In patients with severe COPD, a significant decline of the overall cognitive function and especially of the verbal memory can be observed.1

Special research has also been done on the impact of COPD and chronic hypoxaemia on the auditory function of these patients. Laboratory results showed a statistically significant difference for all auditory measures between patients with COPD and controls, but in general hearing impairment to date was not shown to be clinically relevant in patients with COPD.5,6 Also in stable patients with COPD and mild-to-moderate airflow obstruction, subclinical abnormalities of brainstem auditory evoked potentials have been observed.7 It remains unclear if these results would have any clinical relevance for unselected patients with COPD in all stages in the general practice setting.8 Other chronic conditions such as hypertension, diabetes or cardiovascular disease, which have been shown to deteriorate hearing as well, are frequently met in patients with COPD.

Strengths and limitations of this study

- A key strength of this study lies in the recruitment of regular patients and controls in primary healthcare, considering major clinically relevant comorbidities and increasing statistical power by an individual 1:1 matching as well as by using questions and tests that could be integrated in the daily work of general practices.

- Limitations of our study include the selection process of the 12 participating general practitioners who were recruited at various continuing medical education activities, the small number of practices, the over-representation of males in the study group, as well as a relatively low number of patients with chronic obstructive pulmonary disease COPD stage III/IV.
making it difficult to judge the role of COPD. Therefore, an individual matching of patients suffering from COPD versus controls in the general practice setting was regarded to be most appropriate to answer the research question whether COPD is a significant and relevant risk factor for a hearing disorder to be considered in primary care.

METHODS

Study design and setting

This study is a comparison of individually 1:1 matched patients suffering from COPD to comparable controls according to age and sex without COPD, but alike comorbidities such as hypertension, diabetes, coronary heart disease and chronic heart failure. The aim of this study is to evaluate whether COPD is a clinically relevant risk factor for hearing impairment. The presence of a hearing impairment was detected by questions and tests applicable in general practice.

The main outcome measure is a sensorineural hearing impairment as assessed in bone conduction by pure tone audiometry (PTA) on the better ear using the average of the frequencies 0.5, 1 and 2 kHz. Secondary outcome measures are the results of the whispering voice test (WVT), the Hearing Handicap Inventory for the Elderly Screening Version (HHIE-S) (see online supplementary files 1 and 2) and the answer to three questions concerning self-perceived hearing problems.

Selection of patients with COPD and controls

Included were consecutive patients diagnosed in general practice with COPD stages I–IV (ICD 10: J44.0, J44.1, J44.8, J44.9; ICPC 2: R95) and suitable controls with a minimum age of 35 years recruited by 12 general practitioners (GPs) from their own practices in the province of Lower Austria in the years 2009 and 2010. The GPs were approached by the authors at various continuing medical education activities and asked to participate. The recruitment of patients and controls took place in all 12 surgeries until a statistically sufficient number of 97 cases (clearly surpassing the required minimum of 60) was reached. COPD cases were selected in the order they came to get their regular (not only COPD-specific) prescriptions. Matching controls from the same 12 surgeries were selected by searching the electronic records and randomly allocated to COPD cases. Of the 100 recruited patients with COPD, 3 refused to participate, so finally 97 patients and 97 controls could be included. The diagnosis of COPD required the fulfilling of the GOLD criteria and the affirmation of the diagnosis by a pulmonary physician documented in the electronic record of the participating GP.

Excluded were bedridden patients and patients unable to give their consent (eg, patients with dementia). Controls were matched 1:1 according to age group (range 5 years), sex and the presence of diabetes, hypertension, coronary heart disease and chronic heart failure.

Additionally, all participants were tested by a mobile research team in the respective practice offices using spirometry, audiometry and a questionnaire to assess the actual pulmonary function of patients with COPD, to assure a normal lung function of controls, to assess a possible hearing impairment by bone-conduction and air-conduction PTA and to investigate the impact of a hearing impairment on social life as measured by HHIE-S.

All participants were clinically stable at the time of testing and used their standard medication. The study was approved by the Ethics Committee of Lower Austria. All participants provided written informed consent. Neither the participating GPs nor the tested participants received financial remuneration for their participation.

Spirometry

Forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and the FEV1/FVC ratio were determined (Spirolab III spirometer; Medical International Research (MIR); Rome, Italy). Spirometries were performed by a medical assistant with operating experience over several years. In addition, an extra preparatory training of 3 h was given to consider various aspects of the specific study situation.

Audiometry

The primary outcome measure was a hearing loss in bone conduction assessed by PTA (ST 20 KL audiometer; MAICO Diagnostic GmbH; Berlin, Germany) on the better ear using the frequencies 0.5, 1 and 2 kHz. According to a broadly accepted definition of a sensorineural hearing impairment, the average of the hearing loss at the frequencies of 0.5, 1 and 2 kHz in the better ear was calculated. It was also recorded if the patient had a hearing loss exceeding 40 dB at the frequencies of 1 or 2 kHz in both ears or at 1 and 2 kHz in one ear according to the definition of a relevant hearing impairment given by Ventry and Weinstein.

Additional questions, testing and application of the HHIE-S questionnaire

The patients were asked three questions concerning problems with hearing in general or in a face-to-face or group conversation. We then applied the WVT and asked the patient to complete the Hearing Handicap Inventory for the Elderly, Screening version questionnaire (HHIE-S) in a validated German language version.

Protocol

Patients with COPD and controls were asked to come to the surgery of their GP in the morning of the study day and to take their usual medication. After being informed about the aim of the study and procedures, patients with COPD and controls were asked to sign an informed consent form. Then the demographic and baseline characteristics of the patient with COPD or the control...
were recorded. This was followed by an inspection of the outer ear canal for a possible obstruction due to ear wax or other abnormalities of the ear canal or eardrum (eg, perforation). Subsequently, the three aforementioned questions concerning a self-perceived hearing disorder were asked, followed by a filling in of the HHIE-S questionnaire and performing the WVT. WVT is an easily applicable screening test for hearing impairment in general medicine. In short: The examiner stands arm’s length (0.6 m) behind the seated person and whispers a combination of numbers and letters (eg, 4-K-2) and then asks the patient to repeat the sequence. Each ear is tested separately and the test can be repeated once with a different combination of three numbers/letters. The test is passed if at least three out of a possible six numbers/letters are repeated correctly.

Afterwards, the patient was tested by pure-tone audiometry to detect a hearing loss in air or bone conduction.

Finally, the lung function of patients with COPD and of the controls was tested by spirometry. The whole testing procedure lasted between 25 and 30 min.

All testing was done by the research team consisting of one GP and one practice assistant in the absence of the patient’s own GP.

In addition to the demographic and baseline characteristics, the research team recorded the smoking status, an occupational exposure to noise, the body mass index, the O2 saturation and the pCO2 of the patients with COPD measured in the practice office of the lung specialist within the past 2 years, the usage of a long-term oxygen therapy (LTOT) and the diagnosis of a depression (F32) as defined by ICD-10, as there is strong evidence for a high prevalence of anxiety and depression in chronic breathing disorders as well as for its significant association with subsequent all-cause mortality.

### Statistical analysis

The data were recorded and analysed using Epi Info, V3.2.2, CDC, Atlanta, Minitab 17 and the R Language and Environment for Statistical Computing and Graphics, V2.9. Standard methods are used for the description of the data (frequencies and percentages for categorical data, mean and SD for continuous data). Differences and correlations between groups were calculated by paired t test, χ2 test, analysis of variance (ANOVA), Pearson’s correlation coefficient and linear regression. Univariate conditional logistic regression analysis for the healthy group and the COPD group was computed for the hearing impairment variables controlling for matching variable age. All other matching variables were perfectly matched and were thus not included in the model. p Values, ORs and the corresponding 95% CIs are reported. Multiple conditional logistic regression analyses were performed for the significant variables.

A p value <0.05 was considered to indicate statistical significance.

### Sample size calculation

Previous audiometries in patients without COPD which were performed due to other reasons resulted in a mean hearing loss of 12.5 dB (SD 11.3). Using a paired t test with a significance level of 0.05 (α) to detect a hearing loss of 18.5 dB in the COPD group compared to 12.5 dB in the control group, assuming an SD of 11.3 dB for both groups, resulted in a total number of 120 (cases and controls) with a statistical power of 80%. The total number of participants in the present study is 194 and clearly surpasses the required minimum. As patients with COPD were matched to controls with regard to age, sex and significant comorbidities, a higher statistical power can be expected.

### RESULTS

Demographic parameters and proportions of relevant comorbidities of the 12 participating surgeries as well as demographic data of the Austrian population are listed in table 1. The participating surgeries show a good comparability in all demographic parameters and the proportion of comorbidities used for matching. It is of interest that the mean age of males and females 35+ years in the surrounding health districts is 59.4 years, whereas the mean age of COPD cases and controls in the investigated surgeries is 65.5 years, which parallels the higher global mean age of 49.6 years found in surgery patients, in comparison to the mean age of 41.4 years in the Austrian population, pointing in the direction of a higher mean age in the investigated surgeries.24 It is of further interest that the overall prevalence of COPD in our study population was as low as 4.5%, which is in accordance with the results of the Austrian data of the Burden of Obstructive Lung Disease (BOLD) study in which a doctor-diagnosed COPD was found in only 5.6% in the general population.25

A total of 194 study participants (97 cases and 97 controls) (144 males; 50 females) with a mean age of 65.5 years (SD 10.2) years were tested. Ages ranged from 36 to 91 years. Participants’ baseline data of cases and controls are listed in table 2.

COPD prevailed in men, as only one quarter of cases and controls were females, a finding which is only partly explainable by the distribution between the sexes (55% males in COPD cases) found in the surgeries and which is only partly supported by the literature.26 27 The most frequent comorbidity was hypertension with more than a half of the cases, followed by coronary heart disease, diabetes and chronic heart failure, all in the range from 18% to 12%. As expected from epidemiological data, the portion of smokers in the COPD group exceeded three quarters.28 11 cases (11.3%) of patients with COPD needed LTOT, two belonging to the COPD III stage and nine to the COPD IV stage. The mean pO2 and pCO2 values were 64.5 mm Hg (SD 9.3) and 39.8 mm Hg (SD 7.0), respectively, values which reflect a
stable and controlled clinical condition of patients with COPD typical for primary care, which in accordance with the literature does not cause a significant impact on the cognitive function of patients with COPD. As expected, the mean percentage of FEV1 (58% of predicted value) was markedly reduced in patients with COPD and in accordance with the fact that the majority of them belonged to COPD stage II (FEV1 50–80%).

25.8% of participants suffering from COPD and 10.3% of controls had a diagnosis of a depression in the electronic health record of the GP.

Figure 1 shows the distribution of male and female COPD cases according to different stages with the majority of cases belonging to stage II. This distribution differs from the published national Austrian and international data of the general population investigated by the BOLD study which found a percentage of 34% of COPD II and 61% of COPD stage I. No significant differences in the mean hearing loss between the different COPD stages I–IV were detectable by ANOVA (p value=0.7).

By testing the age cohort—correlation of hearing loss in the COPD and control groups, we calculated the Pearson correlation coefficients of medium strength (0.56, 0.61, p value<0.001) in the COPD and control groups, respectively. In addition, we investigated the age-dependency of hearing loss in the COPD and control groups by linear regression. A very similar rise in hearing loss with increasing age was found in the COPD (coefficient 0.78) and control groups (coefficient 0.80), but differing constant terms in the COPD (−23.58) and control groups (−28.77) indicates a tendency towards an overall higher hearing loss in the COPD group (all p values<0.001).

Testing for the main outcome measure by t test resulted in a significant difference in the mean bone conduction hearing loss in the PTA as well as in the score of the HHIE-S questionnaire (tables 3 and 4).

We also assessed the medication of commonly prescribed drugs known to cause a hearing impairment like ACE inhibitors, AT2-receptor antagonists, furosemid, torasemid, xipamid, NSAIDs and ASA, opioids, chloroquine and a history of chemotherapy by using a χ2 test which resulted in non-significant ORs in COPD cases and matched controls. The prescription of antibiotics could not be investigated reliably from the EHRs of the GPs due to the high probability of a short time prescription by other physicians without recalling this by the patient, leading to a considerable information bias.

Table 1 Demographic parameters and proportions of relevant comorbidities in 12 participating surgeries and demographic data of the Austrian population

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Controls (n=1967)</th>
<th>COPD (n=97)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean number (N) of patients/surgery/year</td>
<td>N=1967 (SD 373)</td>
<td>N=97</td>
</tr>
<tr>
<td>Mean age (years) of patients visiting surgeries</td>
<td>49.6 years (SD 3.2)</td>
<td>58 (19.5)</td>
</tr>
<tr>
<td>Distribution between the sexes (%) in surgeries</td>
<td>45.3% males 54.7% females (SD 3.8)</td>
<td>58 (19.5)</td>
</tr>
<tr>
<td>Average proportion (%) of COPD cases in surgeries</td>
<td>4.5% (SD 2.3)</td>
<td>61%</td>
</tr>
<tr>
<td>Distribution between the sexes (%) in COPD cases in surgeries</td>
<td>55% males 45% females (SD 3.8)</td>
<td>61%</td>
</tr>
<tr>
<td>Average proportion (%) of FEV1 cases in surgeries</td>
<td>8.5% (SD 2.8)</td>
<td>19%</td>
</tr>
<tr>
<td>Average proportion (%) of hypertension cases in surgeries</td>
<td>23.2% (SD 3.9)</td>
<td>23%</td>
</tr>
<tr>
<td>Average proportion (%) of coronary heart disease cases in surgeries</td>
<td>5.7% (SD 1.3)</td>
<td>5.7%</td>
</tr>
<tr>
<td>Average proportion (%) of chronic heart failure cases in surgeries</td>
<td>2.5% (SD 1.1)</td>
<td>2.5%</td>
</tr>
<tr>
<td>Mean age of the whole population of Austria 2010</td>
<td>41.4 years</td>
<td>58 (19.5)</td>
</tr>
<tr>
<td>Distribution between the sexes (%) in Austria 2010</td>
<td>49% males 51% females</td>
<td>61%</td>
</tr>
<tr>
<td>Mean age of males and females &gt;35 years in surrounding health districts</td>
<td>59.4 years</td>
<td>61%</td>
</tr>
</tbody>
</table>

COPD, chronic obstructive pulmonary disease.

Table 2 Baseline data of participants with COPD and controls (matched according to age, sex, hypertension, coronary heart disease, diabetes and chronic heart failure)

<table>
<thead>
<tr>
<th>Baseline personal data</th>
<th>Participants with COPD (n=97)</th>
<th>Controls (n=97)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD) age</td>
<td>65.5 (10.1)</td>
<td>65.4 (10.4)</td>
</tr>
<tr>
<td>Women, N (%)</td>
<td>25 (25.8)</td>
<td>25 (25.8)</td>
</tr>
<tr>
<td>Hypertension, N (%)</td>
<td>54 (55.7)</td>
<td>54 (55.7)</td>
</tr>
<tr>
<td>Coronary heart disease, N (%)</td>
<td>18 (18.6)</td>
<td>18 (18.6)</td>
</tr>
<tr>
<td>Diabetes, N (%)</td>
<td>15 (15.5)</td>
<td>15 (15.5)</td>
</tr>
<tr>
<td>Chronic heart failure, N (%)</td>
<td>12 (12.5)</td>
<td>12 (12.5)</td>
</tr>
<tr>
<td>Smoking, N (%)</td>
<td>74 (76.2)</td>
<td>34 (35.1)</td>
</tr>
<tr>
<td>Mean (SD) of BMI</td>
<td>29.6 (SD 5.5)</td>
<td>28.9 (SD 4.3)</td>
</tr>
<tr>
<td>Mean duration of COPD (years)</td>
<td>10.2 (SD 6.9)</td>
<td>11 (11.3)</td>
</tr>
<tr>
<td>LTOT, N (%)</td>
<td>64.5 (9.3)</td>
<td>39.8 (7.0)</td>
</tr>
<tr>
<td>Mean (SD) PaO2 (mm Hg)</td>
<td>58 (19.8)</td>
<td>86 (19.5)</td>
</tr>
<tr>
<td>Mean (SD) PaCO2 (mm Hg)</td>
<td>25 (25.8)</td>
<td>10 (10.3)</td>
</tr>
</tbody>
</table>

*PO2 and pCO2 values were available in only 64% of the participants with COPD.

BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; LTOT, long-term oxygen therapy.
To evaluate the influence of other variables on the observed differences of mean bone conduction hearing loss and the HHIE-S total score, a univariate conditional logistic regression analysis was performed.

Table 5 shows the results for the hearing variables, occupational noise exposure, smoking and depression controlling for age. Significant differences in the hearing parameters between COPD cases and controls were only observed in the mean value of the (sensorineural) hearing loss at the frequencies of 0.5, 1 and 2 kHz in the bone conduction of the better ear (p=0.0098) and in the total score of HHIE-S (p=0.043).

The result of the multiple conditional logistic regression for the significant variables shows that smoking (OR 9.72, 95% CI 3.62 to 26.05, p<0.0001) remained a significant factor, but that the mean value of the hearing loss at the frequencies of 0.5, 1 and 2 kHz in the bone conduction of the better ear turned out to be non-significant (OR 1.03, 95% CI 0.98 to 1.07, p=0.23) and that depression (OR 2.44, 95% CI 0.88 to 6.78, p=0.09) and the HHIE-S total score (OR 1.01, 95% CI 0.96 to 1.06, p=0.72) lost its significance as well.

**DISCUSSION**

The results of this study do not support the hypothesis that there is a clinically relevant difference in the hearing performance of patients with COPD which can be measured with practicable tools for use in general medical practice. This was assessed by pure tone bone-conduction and air-conduction audiometry (PTA), the WVT, the application of HHIE-S and by asking three questions concerning a self-perceived hearing disorder. Therefore, routine diagnostic testing for hearing impairment of elderly patients with COPD do not provide benefits which go beyond possible benefits of screening for hearing loss in the general population in elderly patients. However, our study confirmed findings of other authors that cigarette smoking is a significant risk factor for hearing loss. As known in other epidemiological studies and in accordance with the literature, we could observe significantly more cases of depression in patients suffering from COPD when applying univariate logistic regression analysis. Since patients were matched with respect to other common chronic diseases known to be risk factors for a depression (eg, diabetes), the magnitude of association between COPD and depression could have been weakened.

Though we found a small but significant difference in the mean hearing loss in bone conduction as well as in the HHIES total score, further analysis using multiple conditional logistic regression analysis for the significant variables, however, resulted in a loss of significance of the HHIES score and mean hearing loss in bone conduction, so only smoking retained its significance as a risk factor in COPD patients.

One reason to initiate this study was our clinical impression that patients with COPD more often show a hearing impairment. Although there is evidence from specialised research in auditory laboratories that COPD and chronic hypoxaemia have a measurable impact on the auditory function of patients suffering from COPD concerning significant differences for all auditory parameters.

**Table 3** t Test (for paired data) for a difference in mean bone conduction hearing loss (better ear) in COPD cases and controls

<table>
<thead>
<tr>
<th>COPD cases and controls tested by PTA</th>
<th>Mean bone conduction hearing loss (better ear) in dB</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD cases N=97</td>
<td>27.9 (SD 14.2)*</td>
</tr>
<tr>
<td>Controls N=97</td>
<td>23.7 (SD 13.5)</td>
</tr>
</tbody>
</table>

*Significant difference p=0.006. COPD, chronic obstructive pulmonary disease; PTA, pure tone audiometry.

**Table 4** t Test (for paired data) for a difference in the HHIES total score in COPD cases and controls

<table>
<thead>
<tr>
<th>COPD cases and controls tested with HHIE-S</th>
<th>HHIE-S total score</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD cases N=97</td>
<td>7.79 (SD 8.56)*</td>
</tr>
<tr>
<td>Controls N=97</td>
<td>5.53 (SD 8.08)</td>
</tr>
</tbody>
</table>

*Significant difference p=0.036. COPD, chronic obstructive pulmonary disease; HHIE-S, Hearing Inventory for the Elderly, Screening Version.

measures, clinically relevant differences between an individually matched group of patients with COPD and controls with the same relevant comorbidities in the general practice setting of this study are not detectable. The lack of differences in the mean hearing loss between different COPD stages can possibly be explained by the high number of cases with a near-normal pO2, by an individually different susceptibility to a low pO2 and by the difficulty of judging the influence of LTOT.

Besides all considerations on hearing impairment, the study confirmed the correlation of COPD and smoking, as we detected a much larger number of smokers in the COPD group.

Strengths and limitations
To the best of our knowledge, this is the first matched cohort study to investigate the role of COPD as a possible risk factor for hearing impairment which was performed in comparable average general practices using individual matching to increase the statistical power. The strength of our study lies in the recruitment of regular patients and controls in primary healthcare, considering major clinically relevant comorbidities by matching. Although the study needed extra time, it is shown that the questions and tests used in the study could be integrated in the daily work of average general practices. By these measures, we were able to clarify that COPD is not a significant risk factor for a clinically relevant hearing impairment in the general practice setting.

There are some limitations in our study, especially concerning the selection process of the 12 participating GPs who were recruited at various continuing medical education activities.

Since only one quarter of the study population were females, a selection bias cannot be excluded, although an inquiry at the biggest health insurance company of Lower Austria (covering approximately 63% of all insured) concerning the prescription of COPD-specific anticholinergic drugs (ATC R03BB) revealed significantly more prescriptions in males (OR m/f:1.59, CI 1.55 to 1.64, p<0.0001) (MS, personal communication, 2015). Also, since there is evidence in the literature that women may be more vulnerable to smoking, the results of our study could underestimate the influence of COPD on hearing impairment in women.

We could test patients and controls in only a relatively small number of practices in just two health districts of Lower Austria which impairs the generalisation of our findings.

The testing was not done blinded, as the mobile testing team knew if the patient suffered from COPD or not. Since the majority of our cases belonged to the COPD II group, the chronic hypoxia was perhaps not severe enough to cause a pronounced and clinically meaningful effect on the inner ear, leading to a more conservative estimate of the differences.

Implication for clinical practice and public health
Though COPD is a chronic disease affecting various organ systems and also causing a significant influence on the auditory function, the clinical relevance in the primary care setting is not given. We therefore cannot recommend a special screening for hearing impairment in elderly patients with COPD.

Unanswered questions and future research
Since the number of COPD GOLD III/IV cases with and without LTOT was low in our study, the possibility of a clinically relevant hearing impairment in this group of patients cannot be excluded. To overcome the study’s limitations concerning the low number of COPD stage III/IV cases,
the low number of practices as well as the over-representation of women, the study should be re-performed with a larger set of COPD GOLD III/IV patients.

Author affiliations
1Department of General Practice, Centre for Public Health, Medical University Vienna, Vienna, Austria
2Department of General Medicine, Surgery for adults Velky Biel, Velky Biel, Slovakia
3Karl Landsteiner Institute for Systematics in General Medicine, Angern, Austria
4General Practice and Family Medicine, Institute of General Practice and Family Medicine, Witten/Herdecke University, Witten, Germany
5Centre for Public Health, Medical University Vienna, Vienna, Austria
6Center for Medical Statistics, Informatics and Intelligent Systems, Medical University Vienna, Vienna, Austria

Acknowledgements The authors thank Mag. Manfred Hinteregger, member of the Austrian health and social insurance companies, for providing the literature on frequencies of COPD in Austria and Europe, and the staff of the NOEGKK (Lower Austrian area health insurance) for providing data on prescription frequencies of specific anticholinergic drugs used in COPD treatment in male and female patients (MS, personal communication, 2015).

Contributors GK initiated the study and contributed to data acquisition; GK, WF and SZ contributed to the conception and design of the study; GK, AS and SZ did the statistical analyses. All authors contributed to the interpretation of the results. WS was involved in developing the research questions and in analysing the data. He also contributed in drawing the scientific conclusions from the results and in writing the paper. JB contributed to the literature research and draft of the manuscript. All authors critically revised the manuscript for important intellectual content. GK and SZ had full access to the data of the study and take responsibility for its correctness and completeness. All authors made a significant contribution to the research and the development of the manuscript and approved the final version for publication. GK and SZ are the guarantors.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests 'All authors have completed the Unified Competing Interest form at http://www.icmje.org/downloads/coi_disclosure.pdf and declare: no support from any organization for the submitted work; GK reports grants for the "Karl Landsteiner Institute for Systematics in General Medicine" from Actavis, Novartis, Richter Pharma, Kvizda, Boehringer-Ingelheim, Merck, Menarini NOEGAM (Lower Austrian Society for General Practice) and personal fees for reviews of the German translation of the EBM Guidelines for General Medicine (Editor: "Österreichischer Aarztereview"); there are no other relationships or activities that could have influenced the submitted work'.

Patient consent Obtained.

Ethics approval The study was approved by the Ethics Committee of Lower Austria.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
9. de Moraes Marchiori LL, de Almeida Rego Filho E, Matsuo T. No additional data are available.


Correction


The author Jana Bendova has a second affiliation that was left out of the article. The new author affiliation list should be:

Gustav Kamenski,1 Jana Bendova,2 3 Waltraud Fink,4 Andreas Sönnichsen,5 Wolfgang Spiegel,6 Sonja Zehetmayer7

1Department of General Practice, Centre for Public Health, Medical University Vienna, Vienna, Austria
2Department of General Medicine, Surgery for adults Velky Biel, Velky Biel, Slovakia
3Medical Faculty of the Slovak Health University, Bratislava
4Karl Landsteiner Institute for Systematics in General Medicine, Angern, Austria
5General Practice and Family Medicine, Institute of General Practice and Family Medicine, Witten/Herdecke University, Witten, Germany
6Centre for Public Health, Medical University Vienna, Vienna, Austria
7Center for Medical Statistics, Informatics and Intelligent Systems, Medical University Vienna, Vienna, Austria

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

*BMJ Open* 2016;6:e008247corr1. doi:10.1136/bmjopen-2015-008247corr1
Questions and scoring outline for the Hearing Handicap Inventory for the Elderly-Screening Version (HHIE-S)*

Answer (and score)
Question Yes (4) Sometimes (2) No (0)
E-1: Does a hearing problem cause you to feel embarrassed when meeting new people?
E-2: Does a hearing problem cause you to feel frustrated when talking to members of your family? - -
S-1: Do you have difficulty hearing when someone speaks in a whisper? --
E-3: Do you feel handicapped by a hearing problem?
S-2: Does a hearing problem cause you difficulty when visiting friends, relatives or neighbours?
S-3: Does a hearing problem cause you to attend religious services less often than you would like?
E-4: Does a hearing problem cause you to have arguments with family members?
S-4: Does a hearing problem cause you difficulty when listening to television or radio?
E-5: Do you feel that any difficulty with your hearing limits or hampers your personal or social life?
S-5: Does a hearing problem cause you difficulty when in a restaurant with relatives or friends? - - -

*Reproduced from Ventry and Weinstein10 with modification and permission from the publisher.
Dear Prof. Weinstein, dear Barbara!

I want to thank you very much for the permission to use the HHIE-S in my project and for your very quick response!

Kind regards

Gustav

-----

Gustav

Primary care physicians have found the hhi to have great utility. It sounds like a wonderful project and. I would be honored for you to use it in your work

Kind regards

Barbara

Sent from my Verizon Wireless BlackBerry

-----

Dear Professor Weinstein!

Brent Jacocks, Director of the Publishing Services of ASHA, was so kind to give me your e-mail adress. The reason for this was, that I would like to use the HHIE-S in an epidemiological case-control study in 12 primary care practices in Austria to find out if there exists a clinical relevant association between chronic obstructive pulmonary disease (COPD) and a hearing impairment. This question was already investigated in some specialised audiological laboratories. It turned out that there is some negative influence of COPD on the auditory function of the patients, which could be demonstrated for example, by pathological brainstem auditory evoked potentials (BAEP). Anyhow it remained unclear if these changes would have any relevant meaning for COPD patients in the general practice setting.

As the HHIE-S measures the impact of an impaired hearing on social life, it would be an ideal instrument to find out if this impact caused by COPD is relevant.

Therefore I would like to ask you, as the author of the HHIE, for the permission to use the HHIE-S in this academic study in a limited number of approximately 200 cases and controls. I would appreciate it very much if you could give me a positive answer to my request!

Sincerely,
Gustav Kamenski

Dr. Gustav Kamenski
General practitioner and family doctor in private practice
Lecturer for General Medicine
Center for Public Health, Medical University Vienna
Private address:
A 2261 Angern, Austria
Ollersbachgasse 144
Tel. +43-2283-2226
Fax +43-2283-2226